Mushroom Industry & Market Trends
11.2% CAGR
The global functional mushroom market grew at 11.2% annually and was valued at approximately $31.7 billion in 2023, according to Grand View Research — but that number only makes sense once you understand what it includes.
Grand View Research, Functional Mushroom Market Report, 2023
42%
increase in mushroom-infused beverage product launches between 2022 and 2025 (Yang et al., 2025)
~50%
of edible mushroom species qualify as functional foods with documented bioactives (Niego et al., 2021)
7
peer-reviewed studies cited in this guide
Grand View Research, Functional Mushroom Market Report, 2023
View as image ↗If you've looked at functional mushroom market data recently, you've probably encountered a confusing range of numbers. Grand View Research values the market at $31.71 billion in 2023. Fortune Business Insights projects $51.87 billion by 2030. Mordor Intelligence estimates $12.06 billion for 2025. All three are citing the same industry, in roughly the same time period, and arriving at numbers that differ by a factor of four.
The functional mushroom market size depends entirely on what you count as "the market." Once that scope question is resolved, the numbers tell a consistent story about an industry with genuine structural growth drivers, a 2026 correction worth understanding, and a long-term trajectory that peer-reviewed science is helping to explain.
Key Takeaways
- Market size estimates for functional mushrooms range from ~$12B to ~$36B for 2023-2025 because different firms include different segments: supplements-only (Mordor) vs. supplements plus food, beverage, pharmaceutical, and cosmetics (Grand View Research)
- The broad-scope market (GVR) was valued at $31.71B in 2023 with an 11.2% CAGR projected through 2030, which would reach $65.83B
- The mushroom-infused beverage segment grew fastest: product launches increased 42% between 2022 and 2025, with mushroom coffee alone exceeding $1 billion in annual sales (Yang et al., 2025)
- Approximately 50% of edible mushroom species qualify as functional foods with documented bioactive properties — beta-glucans, triterpenoids, ergothioneine — which is the scientific underpinning of market claims (Niego et al., 2021)
- Asia-Pacific accounts for approximately 62% of global mushroom production, with China supplying roughly 70% of that — a supply concentration that creates quality traceability challenges (Gopal et al., 2022)
- In 2026, some US retailers reported functional mushroom category sales down 30-40% from 2023 peaks, alongside a wave of M&A consolidation — a shakeout pattern consistent with a maturing market, not a collapsing one
Why Market Reports Show Wildly Different Numbers (Read This First)
The $12B vs. $36B discrepancy isn't a data error. It's a scope problem, and no one explains it.
When Mordor Intelligence values the functional mushroom market at $12.06 billion for 2025, they are measuring dietary supplements specifically: capsules, powders, tinctures, and extract products labeled as supplements and sold through health food and online retail channels. This is the narrow definition.
When Grand View Research values the same market at $31.71 billion for 2023, they include supplements plus functional food and beverage products (mushroom coffee, infused snacks, beverages), pharmaceutical and nutraceutical formulations, and some cosmetic and personal care applications. This is the broad definition.
When Fortune Business Insights projects $51.87 billion by 2030, they're using a scope somewhere between these, with different assumptions about compound annual growth rates in emerging segments.
All three are measuring something real. Which number matters depends on what question you're asking. For investors or retailers evaluating the beverage segment, the broad-scope number is more relevant. For someone evaluating the supplement supplement-specifically, the narrow number is more accurate.
This guide uses the GVR broad-scope figures as the primary reference, with specific segment data called out where relevant.
Why the Numbers Disagree
The Same Market, Four Different Sizes — It’s a Scope Problem
Reports differ by a factor of four not because the data is wrong, but because each firm counts a different set of segments. The estimate climbs as the definition widens from “supplements only” to the full category.
Bar length is scaled to each estimate relative to the largest projection ($65.83B). Segment scope shown is cumulative — each broader definition includes everything below it.
Sources: Mordor Intelligence, Grand View Research, and Fortune Business Insights functional / medicinal mushroom market reports (industry estimates, not peer-reviewed).
The Functional Mushroom Market: What the Numbers Actually Say
The global functional mushroom market, using the broad-scope GVR definition, was valued at approximately $31.71 billion in 2023 with a compound annual growth rate of 11.2% projected through 2030, reaching an estimated $65.83 billion.
The North America supplement-specific market (narrower scope, from a different report) was $541.77 million in 2023 and is projected at $1.41 billion by 2030, with a CAGR of approximately 15%.
For individual species in North America, Lion's Mane captured 25.79% of the supplement market share and was the fastest-growing species segment. Reishi held 29.4% of global type share in 2024. Shiitake dominated at approximately 34% of total product value in 2023. Chaga was the fastest-growing species by CAGR at approximately 17.6% — a relatively small base growing very quickly.
In the US specifically, functional mushroom products (supplements and food/beverage combined) reached approximately $1.1 billion in 2023, with supplement sales growing 75.8% in that year alone. That 75.8% growth rate was the largest single-year gain of any ingredient in the top 40 of mainstream retail in 2023, according to American Botanical Council data.
The 37% statistic from a 2024 Nutrition Business Journal survey: 37% of US consumers report eating or drinking functional mushroom products, while only 27% take them in capsule supplement form. This explains why the food/beverage segment projections are higher than supplement-only projections.
For the US market data in detail, see Mushroom Supplement Sales in the US: Market Analysis.
What Makes a Mushroom "Functional": The Scientific Foundation of Market Claims
Market projections are only as durable as the underlying science driving consumer demand. For functional mushrooms, the scientific rationale is more substantial than in many supplement categories.
Niego and colleagues reviewed the bioactive compounds across commercially traded mushroom species in 2021 and found that approximately 50% of edible mushroom species contain documented functional compounds at concentrations relevant to health applications. The primary bioactive categories are beta-glucans (structural polysaccharides with documented immunomodulatory activity), triterpenoids (found in reishi and other species, with research across antioxidant and anti-inflammatory pathways), and ergothioneine (a sulfur-containing compound found at concentrations 10-100 times higher than any other food, with a dedicated human cellular transport mechanism).[2]
Ishara and colleagues in 2022 identified the specific metabolite classes with documented functional properties — polysaccharides, eritadenine, chitosan, and mevinolin — as the scientific underpinning of nutraceutical market claims. Eritadenine, found specifically in shiitake, has cholesterol-reducing activity documented in controlled studies. Mevinolin, also from shiitake, has structural similarity to lovastatin.[4]
Chang and Wasser documented in a 2018 review that the convergence of eastern herbal medicine traditions — where species like reishi, lion's mane, and turkey tail have been used medicinally for centuries — with modern nutraceutical investment and Western consumer demand is the foundational growth driver for this market. This is not a new trend. It's an old one accelerated by the infrastructure of supplement distribution and social media marketing.[1]
Łysakowska and colleagues confirmed in a 2023 review that the scientific literature across functional food applications for medicinal mushrooms is substantial and growing, covering beverages, supplements, and nutraceuticals with documented bioactive properties across multiple species.[5]
The market is built on a real biological foundation. That's not universal in the supplement industry, and it's part of what distinguishes the long-term functional mushroom trajectory from categories built primarily on marketing.
The Beverage Explosion: Fastest-Growing Application Segment
The most consequential recent development in the functional mushroom market is not in the supplement aisle. It's in the beverage section.
Yang and colleagues documented in a 2025 review that mushroom-infused beverage product launches grew 42% between 2022 and 2025. The applications span mushroom coffee (the largest single product type), mushroom tea, hydration drinks, and adaptogen blends. Mushroom coffee alone exceeded $1 billion in annual sales by 2025 and was the most visible consumer touchpoint for functional mushroom demand.[7]
The beverage route to market matters strategically because it bypasses the supplement regulatory framework. Food and beverage products don't make the specific health claims that supplement labels require, and their purchase decision is driven by taste and brand familiarity as much as by health intent. This creates a growth pathway less vulnerable to regulatory tightening than the supplement segment.
Łysakowska et al.'s review of functional food applications confirmed that beverages were the fastest-expanding application category for medicinal mushroom bioactives, with lion's mane cognitive products and chaga antioxidant blends leading new product development.[5]
For a deep dive on the mushroom coffee growth story, see How Mushroom Coffee Became a Billion-Dollar Category.
The Meat Analog Opportunity: A Second Growth Engine
A separate demand driver that most market analyses miss: functional mushrooms as meat alternatives.
Boro and colleagues reviewed the evidence for edible mushrooms as meat analogs in a 2025 paper in Food Research International. Their analysis identified texture, protein content, and umami flavor profile as the properties that make mushrooms effective substitutes for meat in processed food applications. Market development for mushroom-based meat analogs was identified as an emerging secondary growth driver independent of supplement demand.[6]
The timing is relevant. The plant-based protein market (Beyond Meat, Impossible Foods) peaked and corrected significantly between 2022 and 2025. Mushroom-based analogs — not pea protein or soy protein extruded to look like meat, but actual mushroom products like king oyster "scallops" and shiitake-based patties — avoided much of that correction because they present as whole foods rather than highly processed substitutes. This created a growth opportunity in retail and food service channels entirely distinct from the supplement market.
The size of the meat analog segment is small relative to the supplement and beverage segments as of 2026, but the structural growth driver — flexitarian and plant-forward eating trends — is durable in a way that individual supplement trends may not be.
Asia-Pacific Dominance and the Supply Chain Reality
Asia-Pacific accounts for approximately 62% of global medicinal mushroom production, with China alone supplying roughly 70% of the Asia-Pacific total. Japan and South Korea supply approximately 15% and 10% of Asia-Pacific volume respectively.
Gopal and colleagues documented in a 2022 review that this regional dominance reflects both traditional medicine roots — centuries of reishi, shiitake, and lion's mane cultivation in China, Japan, and South Korea — and a modern cultivation infrastructure scaled specifically for export to Western markets. The combination of traditional credibility and industrial scale explains why Asia-Pacific captures both the volume production and the premium product positioning in the category.[3]
The supply chain concentration creates one material risk: quality traceability. When the majority of the world's reishi supply originates in Chinese growing regions, and when the quality control infrastructure for that supply chain is variable, the potential for mislabeling and adulteration enters through the supply chain rather than through any individual manufacturer's decisions. This affects premium Western brands sourcing from Asian producers as much as it affects budget products. For a detailed look at how this quality problem plays out in practice, see Fruiting Body vs. Mycelium: The Great Mushroom Supplement Debate and Mycelium on Grain: Why It's Controversial in the Supplement Industry.
For regional market analysis in depth, see Global Medicinal Mushroom Market: Regional Breakdown.
The 2026 Shakeout: What Retailers Are Reporting
The functional mushroom market's growth story has a short-term complication that most forward projections don't address.
In early 2026, several US natural food retailers reported functional mushroom category sales down 30-40% from 2023 and 2024 peaks. Alongside these sales declines, the category entered a consolidation wave: Real Mushrooms acquired Mushroom Science in one of the more visible M&A transactions, and Giorgi Mushroom Co. acquired L.F. Lambert Spawn Co., a major spawn supplier. The pattern is characteristic of a category transitioning from early growth to market maturity.
The honest read on this: a 30-40% retail sales decline from a category that grew 75.8% in one year represents a correction back toward sustainable levels, not a market collapse. Categories that double in a year often give back 30-40% as the initial excitement wave normalizes. The structural drivers — scientific evidence base, beverage segment expansion, plant-based food trends, Asian traditional medicine credibility — are not affected by a short-term retail correction.
The consolidation activity is, if anything, a positive signal. The brands acquiring competitors (Real Mushrooms, known for quality standards) are the ones with sustainable quality practices. M&A that rewards quality-focused operators accelerates industry credibility in ways that organic growth alone doesn't.
Fact Check
Is the functional mushroom market collapsing?
The claim
“The 2026 sales slump means the functional mushroom boom is over.”
Circulated after several US retailers reported 30–40% category declines from 2023–2024 peaks.
What research shows
MisleadingA 30–40% pullback from a category that grew 75.8% in a single year (2023) is a correction back toward a sustainable baseline, not a structural reversal. The absolute level remains far above pre-2022.
The durable growth drivers — a peer-reviewed bioactive evidence base, the fast-expanding beverage segment, and plant-forward eating trends — are unaffected by a short-term retail correction, and M&A is consolidating toward quality-focused operators.
US natural-retailer category sales reports (2026); structural drivers per Yang et al. (2025) and Niego et al. (2021)
Product Segment Snapshot
Current market composition by species (approximate 2024 data):
- Reishi: 29-31% of global type share. The original medicinal mushroom in both traditional and modern contexts. Highest name recognition globally.
- Shiitake: 34% of total mushroom product value in 2023. The most commercially cultivated species globally and the dominant culinary-to-supplement crossover.
- Lion's Mane: 25.79% of North America supplement market. Fastest-growing species by consumer interest, driven by cognitive health positioning. Demand increased approximately 44% in 2023.
- Chaga: Smallest absolute market but highest CAGR at approximately 17.6% annually. Premium positioning as an antioxidant powerhouse.
- Cordyceps: Athletic performance positioning. Strong in pre-workout and sports nutrition channels. Major growth in combination formula products.
Combination formulas (multi-species products combining lion's mane, reishi, cordyceps, and others) grew approximately 16% annually in the US through 2024 and reached approximately $70 million in sales in 2024, exceeding single-species lion's mane ($25M) and cordyceps ($25M) segments individually.
The 2030 Outlook
The $65.83 billion GVR projection for 2030 implies continued 11.2% CAGR from 2023. This requires the beverage segment to continue expanding (Yang 2025 data supports this), the North American supplement market to sustain its growth from a now-larger base, and the meat analog segment to achieve meaningful retail scale.
The North America supplement-specific projection of $1.41 billion by 2030 (15% CAGR) is actually more conservative than it appears because it comes off a small base. The absolute growth from $541.77M to $1.41B over 7 years requires 15% annually but is a $870M absolute increase across a market now generating $65B+ globally.
The science base is the most durable growth driver. The 2,000+ peer-reviewed studies published between 2015 and 2024 on functional mushroom bioactives built the consumer trust and clinical vocabulary that marketing alone couldn't have created. As Niego et al. and Ishara et al. documented, the compounds in these products have real biological mechanisms — and that foundation supports premium pricing and category credibility in ways that markets built purely on marketing trends do not sustain.[2][4]
For detail on the specific growth drivers powering the long-term trajectory, see The $45 Billion Mushroom Market: Where Is the Growth Coming From? and The Functional Mushroom Market: $50B+ Projected by 2030.
The Bottom Line
The global functional mushroom market is measured at $12-36 billion in 2024 depending on whether scope includes only supplements or the full food/beverage/pharmaceutical/cosmetics category. The broad-scope GVR estimate of $31.71B (2023) with 11.2% CAGR is the most comprehensive baseline. Scientific underpinning from peer-reviewed research on beta-glucans, triterpenoids, and ergothioneine provides a durable growth foundation. The 2026 retail shakeout (30-40% declines at some retailers) is a maturation correction, not a structural reversal, alongside consolidation M&A favoring quality-focused brands.
Frequently Asked Questions
Sources & References
- 1RTHM-00946·Chang, Shu Ting et al. (2018). “Current and Future Research Trends in Agricultural and Biomedical Applications of Medicinal Mushrooms and Mushroom Products (Review)..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
- 2RTHM-01414·Niego, Allen Grace et al. (2021). “Macrofungi as a Nutraceutical Source: Promising Bioactive Compounds and Market Value..” Journal of fungi (Basel.Study breakdown →PubMed →↩
- 3RTHM-01525·Gopal, Judy et al. (2022). “Scrutinizing the Nutritional Aspects of Asian Mushrooms, Its Commercialization and Scope for Value-Added Products..” Nutrients.Study breakdown →PubMed →↩
- 4RTHM-01542·Ishara, Jackson et al. (2022). “Nutraceutical potential of mushroom bioactive metabolites and their food functionality..” Journal of food biochemistry.Study breakdown →PubMed →↩
- 5RTHM-00843·Łysakowska, Paulina et al. (2023). “Medicinal Mushrooms: Their Bioactive Components, Nutritional Value and Application in Functional Food Production-A Review..” Molecules (Basel.Study breakdown →PubMed →↩
- 6RTHM-02059·Boro, Sibo et al. (2025). “Edible mushrooms as meat analogues: A comprehensive review of nutritional, therapeutic, and market potential..” Food research international (Ottawa.Study breakdown →PubMed →↩
- 7RTHM-02215·Yang, Jing-Ya et al. (2025). “Innovative applications of medicinal mushrooms in functional foods and nutraceuticals: a focus on health-boosting beverages..” Frontiers in cellular and infection microbiology.Study breakdown →PubMed →↩